Revolutionizing cancer drug development: Harnessing the potential of basket trials
Cancer · 2024-01 · 130 (2) · 186-200
DOI: 10.1002/cncr.35085 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer, online erschienen am 07.11.2023. Verfasst von Vivek Subbiah und 2 weiteren Autor:innen. Beteiligte Einrichtung: Sarah Cannon Research Institute, Nashville, Tennessee, USA. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 93 Literaturangaben. Gefördert von: Boehringer Ingelheim, Debiopharm, Foundation Medicine, Genentech, Grifols, Guardant, Incyte, Konica Minolta, Medimmune, Merck Serono, Omniseq, Pfizer, Sequenom….
Abstract (Originalsprache)
The landscape of cancer therapy has been transformed by advances in clinical next‐generation sequencing, genomically targeted therapies, and immunotherapies. Well designed clinical trials and efficient clinical trial conduct are crucial for advancing our understanding of cancer, improving patient outcomes, and identifying personalized treatments. Basket trials have emerged as one of the efficient modern clinical trial designs that evaluate the efficacy of these therapies across multiple cancer types based on specific molecular alterations or biomarkers, irrespective of histology or anatomic location. This review delves into the evolution of basket trials in cancer drug development, highlighting their potential prospects and current obstacles. The design of basket trials involves screening patients for specific molecular alterations or biomarkers and enrolling them in the trial to receive the targeted therapy under investigation. Statistical considerations play a crucial role in the design, analysis, and interpretation of basket trials. Several notable examples of basket trials that have led to US Food and Drug Administration approval for uncommon molecular alterations (e.g., NTRK fusions, BRAF mutations, RET and FGFR1 alterations) are discussed, including LOXO‐TRK (ClinicalTrials.gov identifier NCT02122913)/SCOUT (ClinicalTrials.gov identifier NCT02637687)/NAVIGATE (ClinicalTrials.gov identifier NCT02576431)/STARTRK (ClinicalTrials.gov identifiers NT02097810, NT02568267), VE‐BASKET (ClinicalTrials.gov identifier NCT01524978), ROAR Basket (ClinicalTrials.gov identifier NCT02034110), LIBRETTO‐001 (ClinicalTrials.gov identifier NCT03157128), ARROW (ClinicalTrials.gov identifier NCT03037385), FIGHT‐203 (ClinicalTrials.gov identifier NCT03011372), and the National Cancer Institute‐Molecular Analysis for Therapy Choice trial (ClinicalTrials.gov identifier NCT02465060). Basket trials have the potential to revolutionize cancer treatment by identifying effective therapies for patients based on specific molecular alterations or biomarkers rather than traditional histology‐based approaches. Plain Language Summary To gain more knowledge about cancer, improve patient outcomes, and discover personalized treatments, it is crucial to conduct clinical trials efficiently. One effective type of clinical trial is called a basket trial . In basket trials, new treatments are tested on various types of cancer, regardless of their location in the body; instead, researchers focus on specific abnormalities in the cancer cells. Basket trials offer hope that we can find personalized treatments that are more effective for each individual battling cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sarah Cannon Research Institute, Nashville, Tennessee, USA.
- Department of Medicine, Medical College of Wisconsin Cancer Center and Genome Sciences and Precision Medicine Center, Milwaukee, Wisconsin, USA.
- WIN Consortium, Paris, France.
ORCID-Profile: Vivek Subbiah, Razelle Kurzrock
Förderung
- Boehringer Ingelheim, Debiopharm, Foundation Medicine, Genentech, Grifols, Guardant, Incyte, Konica Minolta, Medimmune, Merck Serono, Omniseq, Pfizer, Sequenom…
Zitieren
APA
Subbiah, V., Burris, H. A., & Kurzrock, R. (2024). Revolutionizing cancer drug development: Harnessing the potential of basket trials. Cancer, 130(2), 186-200. https://doi.org/10.1002/cncr.35085
Vancouver
Subbiah V, Burris HA, Kurzrock R. Revolutionizing cancer drug development: Harnessing the potential of basket trials. Cancer. 2024;130(2):186-200. doi:10.1002/cncr.35085
BibTeX
@article{Subbiah2024,
author = {Subbiah, Vivek and Burris, Howard A and Kurzrock, Razelle},
title = {Revolutionizing cancer drug development: Harnessing the potential of basket trials},
journal = {Cancer},
year = {2024},
volume = {130},
number = {2},
pages = {186--200},
doi = {10.1002/cncr.35085}
}
EUVIMED